金吾财讯 | 精密科学(EXAS)盘前走高，暂升8.88%，报71.36美元。消息面上，公司今天公布了其血液检测的结直肠癌（CRC）筛查测试的性能数据。结果显示，对于结直肠癌的敏感性为88.3%，对于高级癌前病变的敏感性为31.2%，在阴性样本通过结肠镜检查确认的特异性为90.1%。这些结果在今天的欧洲肿瘤内科学会（ESMO）大会上通过一场题为“前瞻性收集队列中的多分析物、多癌种早期检测（MCED）血液测试的器官特异性表现”的口头报告中进行了展示。Exact Sciences的董事长兼首席执行官Kevin Conroy表示：“Exact Sciences团队不断创新，旨在缩小筛查差距。这一创新背后的见解反映了我们对癌症生物学的理解以及我们科学能力的强大力量。我们采用了独特的科学方法，通过结合新颖的标记物组合，开发出这款测试，从而获得了超出我们此前预期的数据，提升了血液检测结直肠癌筛查的效果。”
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.